Colorectal Cancer

Q&A With Cathy Eng, MD: Unmet Needs in the Management of Metastatic Colorectal Cancer Care

May 14, 2020

Cathy Eng, MD, speaks to the unmet needs of treatment options in the management of metastatic colorectal cancer.

The Expanding Continuum of Care in Metastatic Colorectal Cancer

May 13, 2020

Colorectal cancer is among the most commonly diagnosed malignancies worldwide, representing 10.2% of all cancer cases. The recent addition of third- and fourth-line therapies that extend survival and improve quality of life has opened up new possibilities in the growing continuum of care for metastatic colorectal cancer.

Implications Arise for Combined Genomic and Epigenomic ctDNA Analysis for CRC Detection

May 04, 2020

“This combined genomic and epigenomic plasma-based ctDNA test continues to demonstrate high sensitivity and specificity which significant implications for its clinical utility of CRC detection,”

Study Investigators Question the Rise of CRC in Young Adult Patients

May 04, 2020

Amir Khan, MD, discusses the possible reasons for the rising incidence of young adult patients with gastric cancer and colorectal cancer at the 2020 Gastrointestinal Cancers Symposium.

Treating Early Onset Colorectal Cancer in Young Adults

April 29, 2020

In an interview with Targeted Oncology following SOGO 2020, Andrea Cercek, MD, discussed the rising incidence of CRC in young adults in detail. She also advised community oncologists who encounter these patients in their clinics.

FDA Approves Novel Diagnostic Assay to Accompany Encorafenib in Treatment of mCRC

April 16, 2020

The FDA has granted approval to the therascreen BRAF V600E Kit as a companion diagnostic to encorafenib, a BRAF inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer harboring a BRAF V600E mutation, as detected by an FDA approved test, in combination with cetuximab after prior therapy.

Exploring Regorafenib and Nivolumab as Treatment for Colorectal Cancer

April 14, 2020

Scott Kopetz, MD, PhD, discusses the combination of regorafenib and nivolumab for patients with colorectal cancerthe combination of regorafenib and nivolumab for patients with colorectal cancer.

FDA Approves Encorafenib Plus Cetuximab in BRAF V600E+ mCRC

April 09, 2020

The FDA has approved the combination of encorafenib and cetuximab as treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy, according to a press release from Pfizer.

FDA Grants Pembrolizumab Priority Review for TMB-High Tumors

April 07, 2020

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Pembrolizumab Meets PFS Milestone for Patients with MSI-H/dMMR mCRC

April 06, 2020

Pembrolizumab demonstrated an improvement in progression-free survival in the first-line treatment of patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer, meeting one of the primary end points of the phase III KEYNOTE-177 trial.